<DOC>
	<DOCNO>NCT02333370</DOCNO>
	<brief_summary>The purpose Phase Ib : 1. determine recommend dose LEE011 combination standard dose letrozole well provide additional safety anti-tumor activity data Asian non-Japanese patient 2. determine recommend dose LEE011 combination standard dose letrozole well provide additional safety activity data Japanese patient 3. evaluate safety anti-tumor activity LEE011 RP2D establish dose escalation part combination standard dose letrozole , fulvestrant tamoxifen plus goserelin Japanese patient .</brief_summary>
	<brief_title>A Phase Ib Dose Escalation Study Combination LEE011 With Letrozole Dose Expansion LEE011 With Hormonal Therapy Treatment Pre- ( With Goserelin ) Postmenopausal Women With Hormone Receptor Positive , HER2-negative , Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Women advance ( locoregionally recurrent metastatic ) breast cancer amenable curative therapy ( surgery and/or radiotherapy ) . Patient histologically and/or cytologically confirm diagnosis estrogen receptor positive and/or progesterone receptor positive breast cancer Patient HER2negative breast cancer Patient adequate bone marrow organ function Patient receive CDK4/6 inhibitor . Patient known hypersensitivity excipients LEE011 letrozole Patients inflammatory breast cancer . Patient receive prior systemic anticancer therapy ( include hormonal therapy chemotherapy ) advance breast cancer Patient currently use anticancer therapy Patient major surgery within 14 day prior start study drug recover major side effect . Patient receive radiotherapy â‰¤ 4 week Patient concurrent malignancy malignancy within 3 year Patient metastases central nervous system ( CNS ) . Patient known history HIV infection Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Hormone receptor positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>LEE011 ,</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Postmenopausal Asian woman</keyword>
	<keyword>Pre Postmenopausal Japanese woman</keyword>
</DOC>